🔎 Trials Near Me

Home › Geographic Atrophy › Arizona

Geographic Atrophy clinical trials in Arizona

5 studies for Geographic Atrophy are looking for participants at sites in Arizona.

Cities in Arizona

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  • Retina Associates Southwest PC, Tucson
RecruitingPhase 2/3
Ages 60 and older · All sexes · Updated Sep 30, 2026 · NCT06635148

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  • Associated Retina Consultants - PHX, Gilbert
  • Associated Retina Consultants, Phoenix
RecruitingPhase 1/2
Ages 55 and older · All sexes · Updated Sep 23, 2026 · NCT07029945

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  • Associated Retina Consultants - Peoria- Site Number : 8400011, Peoria
  • Retina Macula Institute of Arizona- Site Number : 8400028, Scottsdale
RecruitingPhase 1/2
Ages 60 and older · All sexes · Updated Sep 22, 2026 · NCT07215234

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  • Barnet Dulaney Perkins Eye Center-Ophthamalogy, Chandler
  • Barnet Dulaney Perkins Eye Center, Phoenix
  • Associated Retina Consultants, Phoenix
  • and 3 more
RecruitingPhase 3
Ages 50 to 85 · All sexes · Updated Sep 18, 2026 · NCT06541704

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  • Associated Retina Consultants, Gilbert
  • Associated Retina Consultants, Phoenix
RecruitingPhase 2
Ages 55 and older · All sexes · Updated Sep 10, 2026 · NCT06659445

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.